Cargando…
Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
We compared the efficacy of macitentan, a novel dual endothelin A/endothelin B receptor antagonist, with that of another dual endothelin receptor antagonist, bosentan, in a rat model of non-vasoreactive pulmonary hypertension (PH) with particular emphasis on right ventricular (RV) remodeling. METHOD...
Autores principales: | Iglarz, Marc, Landskroner, Kyle, Bauer, Yasmina, Vercauteren, Magali, Rey, Markus, Renault, Berengère, Studer, Rolf, Vezzali, Enrico, Freti, Diego, Hadana, Hakim, Schläpfer, Manuela, Cattaneo, Christophe, Bortolamiol, Céline, Weber, Edgar, Whitby, Brian R., Delahaye, Stéphane, Wanner, Daniel, Steiner, Pauline, Nayler, Oliver, Hess, Patrick, Clozel, Martine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Journal of Cardiovascular Pharmacology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632117/ https://www.ncbi.nlm.nih.gov/pubmed/26230396 http://dx.doi.org/10.1097/FJC.0000000000000296 |
Ejemplares similares
-
Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020) -
Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells
por: Gatfield, John, et al.
Publicado: (2012) -
GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1
por: Zmajkovicova, Katarina, et al.
Publicado: (2020) -
Bosentan and macitentan prevent the endothelial-to-mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study
por: Corallo, Claudio, et al.
Publicado: (2016) -
Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)